Fate Therapeutics Q4 Earnings Summary & Key Takeaways
Benzinga·02/26/2026 14:14:08
Listen to the news
Fate Therapeutics (NASDAQ:FATE) released its Q4 earnings on Thursday, February 26, 2026 at 09:00 AM.
Here's what's important from the earnings announcement.
Earnings
Fate Therapeutics missed estimated earnings by 0.0%, reporting an EPS of $-0.27 versus an estimate of $-0.27.
Revenue was down $491 thousand from the same period last year.
Analysis of Past Earnings
The company beat on EPS by $0.01 in the last quarter, resulting in a 2.85% drop share price change the following day.
Here's a look at Fate Therapeutics's past performance:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.28 | -0.35 | -0.46 | -0.43 |
| EPS Actual | -0.27 | -0.29 | -0.32 | -0.44 |
| Revenue Estimate | 1.35M | 947K | 1.20M | 1.57M |
| Revenue Actual | 1.74M | 1.91M | 1.63M | 1.86M |
To track all earnings releases for Fate Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.